Phase 2 N=184 SYL040012, Treatment for Open Angle Glaucoma
Open Angle Glaucoma · Ocular Hypertension
Primary: Change From Baseline in the Mean Diurnal IOP Within Each Treatment Arm — -2.4; -3.2; -3.1; -3.1 mmHg — p=0.93
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=259 A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Onychomycosis of the Toenail
Onychomycosis
Primary: The Proportion of Subjects in the Intent-to-treat Population With Complete Cure, Defined as Clinical AND Mycological Cure, at Week 48 — 17; 19; 22; 18 Participants
Phase 2 N=15 SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study
Chronic Inflammatory Demyelinating Polyneuropathy · Peripheral Neuropathy · Charcot-Marie-Tooth Disease
Primary: Motor Nerve Conduction Velocity (m/Sec) — 1.67 m/s — p=0.7615
Phase 2 N=24 Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma
Biliary Carcinoma · Gall Bladder Carcinoma · Cholangiocarcinoma
Primary: Progression Free Survival (PFS) — 6.2 months
Phase 2 N=24 A Study to Assess the Efficacy of Gefapixant (MK-7264/AF-219), in Participants With Chronic Cough (MK-7264-006)
Chronic Cough
Primary: Change From Baseline in Daytime Objective Cough Frequency — -0.5365; 0.0523 Coughs/hour — p=0.0003
Phase 2 N=24 Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas
Basal Cell Nevus Syndrome · Gorlin's Syndrome
Primary: Time to Recurrence to Baseline SEB Burden Following 7 Months of Continuous Vismodegib Treatment.
Phase 2 N=284 Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant
Myeloproliferative Disorders · Leukemia · Lymphoma
Primary: Number of Participants Who Were Alive at 1 Year Post Transplant — 59; 40; 1; 26 Participants
Phase 2 N=60 A Pharmacokinetics, Safety and Efficacy Study of Tafenoquine (TQ) in Pediatric Subjects With Plasmodium Vivax (P. Vivax) Malaria
Malaria, Vivax
Primary: Area Under the Curve From Time 0 Extrapolated to Infinite Time (AUC[0-infinity]) of Tafenoquine by Weight Band in Participants Aged >=2 Years to <16 Years (Weighing >=5…
Phase 2 N=39 Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer
Prostate Cancer
Primary: Median Tumor Volume Burden at Baseline Multi-parametric Magnetic Resonance Imaging (mpMRI) Before and After Surgery — 3.44; 0.62 cc
Phase 2 N=358 A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis
Primary: Change in Monthly Rate of Decline in ALSFRS-R (Amyotrophic Lateral Sclerosis Functional Rating Score - Revised) — 1.20; 1.01 points per month
Phase 2 N=36 Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis
Dermatomyositis · Polymyositis
Primary: Compare the Average Total Improvement Scores at Visits 2 Through 7 During the 6-month Treatment Period Between the Treatment and Placebo Arms — 26.4; 29.3 score on a…
Phase 2 N=10 Randomized, Double-blind, Placebo-Controlled Pilot Study of MDMA-assisted Therapy for PTSD
Posttraumatic Stress Disorder (PTSD)
Primary: Change in Clinical Administered PTSD Scale (CAPS-IV) Total Score From Baseline to End of Stage 1 — -42.0; -9.0; -34.6 score on a scale
Phase 2 N=286 Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease
Elevated Lipoprotein(a) · Cardiovascular Disease
Primary: Percent Change From Baseline in Fasting Lipoprotein A [Lp(a)] at the Primary Analysis Time Point — -35; -56; -72; -58 percent change — p=0.0032
Phase 2 N=1 Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100
Fanconi Anemia
Primary: Number of Participants Who Safely Received AMD3100 Used in Combination With Standard Dose G-CSF — 1 participants
Phase 2 N=20 Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin
Advanced Digestive System Neuroendocrine Neoplasm · Duodenal Neuroendocrine Tumor G1 · Functional Pancreatic Neuroendocrine Tumor
Primary: Number of Participants With Response Rate Per Response Evaluation Criteria in Solid Tumors Version 1.1 — 19 participants